Evaluation of Immunomodulatory and Therapeutic Properties of Biological Response Modifiers: A Comparison of Preclinical and Clinical Studies

  • James E. Talmadge
  • Carl Pinsky
  • Ronald B. Herberman
  • Cedric Long
  • Paul L. Black


Biological response modifiers (BRMs) are those agents or approaches that modify the relationship between the tumor and host by modifying the host’s biological response to the tumor cells with resultant therapeutic effects (1). BRMs may modify the host responses in several ways:
  1. 1.

    increase the host’s antitumor responses through augmentation and/or restoration of effector mechanisms or mediators of the host’s reaction which may be deleterious;

  2. 2.

    increase the host’s defenses by the administration of natural biologicals (or the synthetic-recombinant derivatives thereof) as effectors or mediators of an antitumor response;

  3. 3.

    augment the sensitivity of the host’s tumor cells to endogenous mechanisms for the control of tumor growth;

  4. 4.

    alter the transformed phenotype by increasing the differentiation/maturation of tumor cells;

  5. 5.

    increase the ability of the host to tolerate damage by cytotoxic modalities of cancer treatment.



Effector Cell Maximum Tolerate Dose Acute Myelogenous Leukemia Therapeutic Activity Tumor Infiltrate Lymphocyte 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    E. Mihich, and A. Fefer (Eds.), Biological response modifiers subcommittee report. In: Natl. Cancer Inst. Monogr. 63, pp. 1–252 (1983).Google Scholar
  2. 2.
    E. Mihich, Biological response modifiers: Their potential and limitations in cancer therapeutics. Cancer Invest. 3, 71–83 (1985).PubMedCrossRefGoogle Scholar
  3. 3.
    R. V. Smalley, and R. K. Oldham, Biological response modifiers: Preclinical evaluation and clinical activity. CRC Crit. Rev. Oncol. Hematol. 1, 259–294 (1984).CrossRefGoogle Scholar
  4. 4.
    R. K. Oldham, Biologicals and biological response modifiers: Design of clinical trials. J. Biol. Resp. Modif. 4, 117–128 (1985).Google Scholar
  5. 5.
    R. B. Herberman, Design of clinical trials with biological response modifiers. Cancer Treat. Rep. 69, 1161–1164 (1985).PubMedGoogle Scholar
  6. 6.
    C. M. Pinsky, Application of phase I trial results in the design of phase II and II biological response modifier trials. Cancer Treat. Rep. 69, 1171–1182 (1985).PubMedGoogle Scholar
  7. 7.
    G. Mathe, J. L. Amiel, L. Schwarzenberg, M. Schneider, A. Cattan, J. R. Schlumberger, M. Hayat, and F. De Vassal, Active immunotherapy for acute lymphoblastic leukemia. Lancet 1, 697–699 (1969).PubMedCrossRefGoogle Scholar
  8. 8.
    R. Heyn, M. Nesbit, P. Joo, M. Karon, W. Borges, D. Hammond, and N. Breslow, Effect of BCG in the duration of the first remission in children with acute lymphoid leukemia. In Neoplasia Immunity: BCG Vaccination 1974 (R. G. Crispen, ed.) pp. 15–23. Schori Press, Evanston.Google Scholar
  9. 9.
    R. L. Powles, D. Crowther, C. J. T. Bateman, M. E. J. Beard, T. J. McElwain, J. Russel, T. A. Lister, J. M. A. Whitehouse, P. F. M. Wrigley, M. Pike, P. Alexander, and G. Fairley, Immunotherapy for acute myelogenous leukaemia. Br. J. Cancer 28, 365–376 (1973).PubMedCrossRefGoogle Scholar
  10. 10.
    J. U. Qutterman, E. M. Hersh, V. Rodriguez, K. B. McCredie, G. Mavligit, R. Reed, M. A. Burgess, T. Smith, E. Gehan, G. P. Bodey, and E. J. Freireich, Chemoimmunotherapy of adult acute leukaemia: Prolongation of remission in myeloblastic leukaemia with BCG. Lancet 2, 1405–1409 (1974).CrossRefGoogle Scholar
  11. 11.
    W. R. Vogler, and Y. K. Chang, Prolonging remission in myeloblastic leukaemia by Tice-Strain Bacillus Calmette-Guerin. Lancet 2, 128–131 (1974).PubMedCrossRefGoogle Scholar
  12. 12.
    K. A. Foon, R. V. Snalley, C. W. Riggs, and R. P. Gale, The role of immunotherapy in acute myelogenous leukemia. Arch. Int. Med. 143, 1726–1731 (1983).CrossRefGoogle Scholar
  13. 13.
    A. Morales, and A. Ersil, Adjuvant BCG immunotherapy in the prophylaxis and treatment of noninvasive bladder cancer. In Immunotherapy of Human Cancer 1982 (W. D. Terry, and S. A. Rosenberg, Eds.) pp. 301–307. Excerpta Medica, New York.Google Scholar
  14. 14.
    C. M. Pinsky, F. J. Camacho, D. Kerr, D. W. Braun Jr., W. F. Whitmore Jr., and H. Oettgen, Treatment of superficial bladder cancer with intravesical BCG. In Immunotherapy of Human Cancer 1982 (W. D. Terry, and S. A. Rosenberg, Eds.) pp. 309–313. Excerpta Medica, New York.Google Scholar
  15. 15.
    D. L. Lamm, D. E. Thor, S. C. Harris, V. D. Stogdill, and H. M. Radwin, Intravesical and percutaneous BCG immunotherapy of recurrent superficial bladder cancer. In Immunotherapy of Human Cancer 1982 (W. D. Terry, and S. A. Rosenberg, Eds.) pp. 315–322. Excerpta Medica, New York.Google Scholar
  16. 16.
    C. Pinsky, F. Camacko, D. Kerr, H, Herr, H. Geller, W. Whitmore, and H. Oettgen, Treatment of superficial bladder cancer with intravesical BCG. Proc. Amer. Soc. Clin. Oncol. 2, 57 (1983).Google Scholar
  17. 17.
    M. F. McKneally, C. Maver, H. W. Kausel, Regional immunotherapy of lung cancer with intrapleural BCG. Lancet 1, 377–379 (1976).PubMedCrossRefGoogle Scholar
  18. 18.
    R. C. Bast, J. S. Berek, R. Obrist, C. T. Griffiths, R. S. Berkowitz, N. F. Hacker, L. Parker, L. D. Lagasse, and R. C. Knapp, Intraperitoneal immunotherapy of human ovarian carcinoma with corynebacterium parvum. Cancer Res. 43, 1395–1401 (1983).PubMedGoogle Scholar
  19. 19.
    A. Uchida, M. Micksche, and T. Hoshino, Intrapleural administration of OK-432 in cancer patients: Augmentation of autologous tumor killer actiivty of tumor-associated large granular lymphocytes. Cancer Immunol. Immunother. 18, 5–12 (1984).PubMedCrossRefGoogle Scholar
  20. 20.
    K. A. Foon, S. A. Sherwin, P. G. Abrams, D. L. Longo, M. F. Fer, H. C. Stevenson, J. J. Ochs, G. C. Bottino, C. S. Schoenberger, J. Zeffren, E. S. Jaffe, and R. K. Oldham, Treatment of advanced non-Hodgkin’s lymphoma with recombinant leukocyte A interferon. N. Engl. J. Med. 311, 1148–1152 (1984).PubMedCrossRefGoogle Scholar
  21. 21.
    J. A. Neidhart, M. M. Gagen, D. Young, R. Tuttle, T. J. Mel ink, A. Ziccarrelli, and D. Kisner, Interferon-a therapy of renal cancer. Cancer Res. 44, 4140–4143 (1984).PubMedGoogle Scholar
  22. 22.
    P. A. Bunn Jr., K. A. Foon, D. C. Ihde, D. L. Longo, J. Eddy, C. F. Winkler, W. R. Veach, J. Zeffren, S. Sherwin, and R. Oldham, Recombinant leukocyte A interferon: An active agent in advanced cutaneous T-cell lymphomas. Ann. Intern. Med. 101, 484–487 (1984).PubMedGoogle Scholar
  23. 23.
    S. A. Sherwin, K. A. Foon, P. G. Abrams, M. R. Heyman, J. J. Ochs, T. Watson, A. Maluish, and R. K. Oldham, A preliminary phase I trial of partially purified interferon-y in patients with cancer. J. Biol Resp. Modif. 3, 599–607 (1984).Google Scholar
  24. 24.
    J. M. Kirkwood, and M. S. Ernstoff, Interferons in the treatment of human cancer. J. Clin. Oncol. 2, 336–352 (1984).PubMedGoogle Scholar
  25. 25.
    E. C. Borden, Interferon and cancer: How the promise is being kept. In Interferons, vol. 5. 1984 (I. Gresser, ed.) pp. 43–83. Academic Press, Orlando, Florida.Google Scholar
  26. 26.
    S. A. Rosenberg, M. T. Lotze, L. M. Muul, S. Leitman, A. E. Chang, Si E. Ettinghausen, Y. L. Matory, J. M. Skibber, E. Shiloni, J. T. Vetto, C. A. Seipp, C. Simpson, and C. M. Reichert, Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Eng. J. Med. 313, 1485–1492 (1985).CrossRefGoogle Scholar
  27. 27.
    J. E. Talmadge, I. J. Fidler, and R. K. Oldham, Screening For Biological Response Modifiers: Methods and Rationale 1985 pp. 1–193. Martinus Nihjoff Publishing, Boston.CrossRefGoogle Scholar
  28. 28.
    J. E. Talmadge, and R. B. Herberman, The preclinical screening laboratory: Evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treat. Rep. 70, 171–182 (1986).PubMedGoogle Scholar
  29. 29.
    V. T. DeVita, Jr., Principles of Chemotherapy. In Cancer — Principles and Practice of Oncology 1985 (V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg, eds.) pp. 257–285 Lippincott, Philadelphia.Google Scholar
  30. 30.
    J. E. Talmadge, A. E. Maluish, M. Collins, M. Schneider, R. B. Herberman, R. K. Oldham, and R. H. Wiltrout, Immunomodulation and antitumor effects of MVE-2 in mice. J. Biol. Resp. Mod. 3, 634–652 (1984).Google Scholar
  31. 31.
    C. M. Hawrylowicz, R. C. Rees, B. W. Hancock, and C. W. Potter, Depressed spontaneous natural killing and interferon augmentation in patients with malignant lymphoma. Eur. J. Cancer Clin. Oncol. 18, 1081–1088 (1982).PubMedCrossRefGoogle Scholar
  32. 32.
    A. E. Maluish, J. R. Ortaldo, J. C. Conlon, S. A. Sherwin, R. Leavitt, D. M. Strong, P. Wiernik, R. K. Oldham, and R. B. Herberman, Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon. J. Immunol. 131, 503–507 (1983).PubMedGoogle Scholar
  33. 33.
    M. J. Brunda, D. Rosenbaum, and L. Stern, Inhibition of experimental ly-induced murine metastases by recombinant alpha interferon: correlation between the modulatory effect of interferon treatment on natural killer cell activity and inhibition of metastases. Int. J. Cancer 34, 421–426 (1984).PubMedCrossRefGoogle Scholar
  34. 34.
    J. E. TaTmadge, J. Adams, H. Phillips, M. Collins, B. Lenz, M. Schneider, E. Schlick, R. Ruffman, R. H. Wiltrout, and M. A. Chirigos, Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcel1ulose. Cancer Res. 45, 1058–1065 (1985).Google Scholar
  35. 35.
    R. H. Wiltrout, B. J. Mathieson, J. E. Talmadge, C. W. Reynolds, S. R. Zhang, R. B. Herberman and J. R. Ortaldo, Augmentation of organ-associated NK activation by biological response modifiers: isolation and characterization of large granular lymphocytes from the liver. J. Exp. Med. 160, 1431–1449 (1984).PubMedCrossRefGoogle Scholar
  36. 36.
    R. H. Wiltrout, R. B. Herberman, S. Zhang, M. A. Chirigos, J. R. Ortaldo, K. M. Green Jr, and J. E. Talmadge, Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver. J. Immunol. 134, 4267–4275 (1985).PubMedGoogle Scholar
  37. 37.
    J. E. Talmadge, M. Schneider, M. Collins, H. Phillips, R. B. Herberman, and R. H. Wiltrout, Augmentation of NKcell activity in tissue specific sites by liposomes incorporating MTP-PE. J. Immunol. 135, 1477–1483 (1985).PubMedGoogle Scholar
  38. 38.
    J. E. Talmadge, B. F. Lenz, M. S. Collins, K. A. Uithoven, M. A. Schneider, J. S. Adams, J. W. Pearson, W. J. Agee, R. E. Fox, and R. K. Oldham, Tumor models to investigate the therapeutic efficiency of immunomodulators. Behring Inst. Mitt. 74, 219–229 (1984).PubMedGoogle Scholar
  39. 39.
    J. E. Talmadge, Immunoregulation and immunostimulation of murine lymphocytes by recombinant human interleukin-2. J. Biol. Resp. Modif. 4, 18–34 (1985).Google Scholar
  40. 40.
    J. E. Talmadge, S. Dennis-Tait, M. A. Schneider, A. K. Meeker, J. S. Adams, In vitro and in vivo stimulation of murine lymphocytes by human recombinant interleukin 2 (rIL-2). In Immunity to Cancer 1985 (A. E. Reif, and M. S. Mitchell, Eds.) pp. 531–537. Academic Press, New York.Google Scholar
  41. 41.
    J. E. Talmadge, H. Phillips, J. Schindler, H. R. Tribble, and R. Pennington, A systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. Cancer Res, in press (1987).Google Scholar
  42. 42.
    P. Kern, J. Toy, and M. Dietrich, Preliminary clinical observations with recombinant interleukin-2 in patients with AIDS or LAS. Blut. 50, 1–6 (1985).PubMedCrossRefGoogle Scholar
  43. 43.
    TT T. Lotze, R. J. Robb, S. W. Sharrow, L. W. Frana, and S. A. Rosenberg, Systemic administration of interleukin-2 in humans. J. Biol. Resp. Modif. 3, 475–482 (1984).Google Scholar
  44. 44.
    H. C. Lane, J. P. Siegel, A. H. Rook, H. Masur, E. P. Gelmann, G. V. Quinnan, and A. S. Fauci, Use of interleukin-2 in patients with acquired immunodeficiency syndrome. J. Biol. Resp. Modif. 3, 512-516 (1984).Google Scholar
  45. 45.
    G. Pizza, G. Severini, D. Menniti, C. De Vinci, and F. Corrado, Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report. Int. J. Cancer 34, 359–567 (1984).PubMedCrossRefGoogle Scholar
  46. 46.
    J. P. Siegel, H. C. Lane, N. I. Stock, G. V. Quinnan Jr., and A. S. Fauci, Pharmacokinetics of lymphocyte-derived and recombinant DNA-derived interleukin-2 after intravenous administration to patients with the acquired immunodeficiency syndrome. J. Biol. Resp. Modif. 4, 596–601 (1985).Google Scholar
  47. 47.
    VT. H. West, K. W. Tauer, J. R. Yarnelli, G. D. Marshall, D. W. Orr, G. B. Thurman, and R. K. Oldham, Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. J. Biol. Resp. Modif. 6, 221 (1987).Google Scholar
  48. 48.
    J. Hank, N. Rosenthal, P. Kohler, B. Storer, and P. Sondel, Peripheral blood lymphocytes obtained following in vivo IL-2 therapy express lymphokine activated killer activity. Fed. Proc. 46, 1509 (1987).Google Scholar
  49. 49.
    S. P. Creekmore, J. E. Harris, T. M. Ellis, D. P. Braun, J. McMannis, I. I. Cohen, N. Bhoopalam, P. F. Jassak, M. A. Cahill, C. L. Canzoneri, and R. I. Fisher, Phase I/I I trial of recombinant interleukin-2 by 24-hr continuous infusion — an Illinois Cancer Council trial. Proc. Amer. Soc. Clin. Oncol. 6, 244 (1987).Google Scholar
  50. 50.
    J. T. Kurnick, R. L. Kradin, L. A. Boyle, and A. Burdeshaw, Assessment of activation of T lymphocytes infiltrating human lung cancers. Fed. Proc. 46, 1341 (1987).Google Scholar
  51. 51.
    J. E. Talmadge, H. R. Tribble, R. W. Pennington, H. Phillips, and R. H. Wiltrout, Immunomodulatory and immunotherapeutic properties of recombinant y-interferon and recombinant tumor necrosis factor in mice. Cancer Res. 47, 2563–2570 (1987).PubMedGoogle Scholar
  52. 52.
    P. L. Black, H. Phillips, H. R. Tribble, R. Pennington, M. Schneider, and J. E. Talmadge, Correlation of immunomodulatory and therapeutic activities of interferon and interferon inducers in metastatic disease. J. Cell. Biochem. in press (1987).Google Scholar
  53. 53.
    E. A. Carswell, L. J. Old, R. L. Kassel, S. Green, N. Fiore, and B. Williamson, An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U.S.A. 72, 3666–3670 (1975).PubMedCrossRefGoogle Scholar
  54. 54.
    K. Haranaka, and N. Satomi, Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cells in vitro. Jpn. J. Exp. Med. 51, 191–194 (1981).PubMedGoogle Scholar
  55. 55.
    K. Haranaka, N. Satomi, and A. Sakurai, Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int. J. Cancer 34, 263–267 (1984).PubMedCrossRefGoogle Scholar
  56. 56.
    B. D. Williamson, E. A. Carswell, B. Y. Rubin, J. S. Predergast, and L. J. Old, Human tumor necrosis factor produced by human B-cell lines: Synergistic cytotoxic interaction with human interferon. Proc. Natl. Acad. Sci. U.S.A. 80, 5397–5401 (1983).PubMedCrossRefGoogle Scholar
  57. 57.
    Y. Sohmura, K. Nakata, H. Yoshida, S. Kashimoto, Y. Matsui, and H. Furuichi, Recombinant human tumor necrosis factor. II. Antitumor effect on murine and human tumors transplanted in mice. Int. J. Immunopharmacol. 8, 357–368 (1986).PubMedCrossRefGoogle Scholar
  58. 58.
    N. Watanabe, Y. Nfitsu, H. Sone, H. Neda, I. Urushizaki, A. Yamamoto, M. Nagamura, and Y. Sugawara, Therapeutic effect of endogenous tumor necrosis factor on ascites Meth A sarcoma. J. Immunopharmacol. 8, 271–283 (1986).PubMedCrossRefGoogle Scholar
  59. 59.
    G. G. MacPherson, and R. J. North, Endotoxin-mediated necrosis and regression of established tumours in the mouse. Cancer Immunol. Immunother. 21, 209–216 (1986).CrossRefGoogle Scholar
  60. 60.
    F. R. Balkwitt, A. Lee, G. Aldam, E. Moodie, J. A. Thomas, J. Tavernier, and W. Fiers, Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res. 46, 3990–3993 (1986).Google Scholar
  61. 61.
    B. B. Aggarwal, T. E. Eessalu, and P. E. Hass, Characterization of receptors for human tumour necrosis factor and their regulation by y-interferon. Nature 318, 665–667 (1985).PubMedCrossRefGoogle Scholar
  62. 62.
    J. E. Talmadge, O. Bowersox, H. Tribble, S. H. Lee, M. Shepard, and D. Liggitt, Toxicity of tumor necrosis factor with interferon-y and can be reduced with cyclooxygenase inhibitors. Amer. J. Path, in press (1987).Google Scholar
  63. 63.
    W. Hryniuk, and M. N. Levine, Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J. Clin. Oncol. 4, 1162–1167 (1986).PubMedGoogle Scholar
  64. 64.
    D. P. Griswold Jr, M. W. Trader, E. Frei III, W. P. Peters, M. K. Wolpert, and W. R. Laster Jr., Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy. Cancer Res. 47, 2323–2328 (1987).PubMedGoogle Scholar
  65. 65.
    D. Hartmann, J. S. Adams, A. K. Meeker, M. A. Schneider, B. F. Lenz, and J. E. Talmadge, Dissociation of therapeutic and toxic effects of polyinosinic-polycytidylic acid admixed with poly-L-lysine and sol ubi1ized with carboxymethyl cellulose in tumor-bearing mice. Cancer Res. 46, 1331–1338 (1985).Google Scholar
  66. 66.
    R. Lafrenlere, and S. A. Rosenberg, Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (rIL 2) can mediate the regression of both Immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J. Immunol. 135, 4273–4280 (1985).Google Scholar
  67. 67.
    R. Sal up, T. C. Bock, and R. H. Wiltrout. Successful treatment of advanced murine renal cell carcinoma by biocompartmental adoptive chemoimmunotherapy. J. Immunol. 138, 641–647 (1987).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • James E. Talmadge
    • 1
  • Carl Pinsky
    • 2
  • Ronald B. Herberman
    • 3
  • Cedric Long
    • 4
  • Paul L. Black
    • 1
  1. 1.Preclinical Screening LaboratoryNCI-Frederick Cancer Research Facility, Program Resources, Inc.FrederickUSA
  2. 2.Office of the Associate Director, Biological Response Modifiers Program, DCTNCI-Frederick Cancer Research FacilityFrederickUSA
  3. 3.Pittsburgh Cancer InstitutePittsburghUSA
  4. 4.Office of the DirectorNCI-Frederick Cancer Research FacilityFrederickUSA

Personalised recommendations